Final FDA Waiver Guidance For Point-Of-Care Diagnostics Unduly Burdensome, Industry Org. Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Long-awaited FDA guidance for point-of-care diagnostics to be used in less-sophisticated settings offers leeway in clinical trial design but not enough for industry.